Evidence map›Paper›PMID 38672560›Full record

ReviewCancers2024

Application of PET/MRI in Gynecologic Malignancies.

Sheida Ebrahimi, Elin Lundström, Summer J Batasin, Elisabeth Hedlund, Karin Stålberg, Eric C Ehman, Vipul R Sheth, Negaur Iranpour, Stephane Loubrie, Alexandra Schlein and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. The Diagnostic and Prognostic Value ofDiagnostics (Basel, Switzerland) · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Sheida EbrahimiDepartment of Radiology, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9611-4261
Elin LundströmDepartment of Radiology, University of California San Diego, La Jolla, CA 92093, USA.
Summer J BatasinDepartment of Radiology, University of California San Diego, La Jolla, CA 92093, USA.
Elisabeth HedlundDepartment of Surgical Sciences, Radiology, Uppsala University, 751 85 Uppsala, Sweden.
Karin StålbergDepartment of Women's and Children's Health, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0001-5527-8796
Eric C EhmanDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Vipul R ShethDepartment of Radiology, Stanford University, Palo Alto, CA 94305, USA.
Negaur IranpourDepartment of Radiology, Stanford University, Palo Alto, CA 94305, USA.
Stephane LoubrieDepartment of Radiology, University of California San Diego, La Jolla, CA 92093, USA.
Alexandra SchleinDepartment of Radiology, University of California San Diego, La Jolla, CA 92093, USA.
Rebecca Rakow-PennerDepartment of Radiology, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-2566-1978
University of California San Diego · USUppsala University · SEPalo Alto University · USMayo Clinic · US

Funding

Advanced diffusion MRI for evaluating early response to radiation treatment in cervical cancerR37CA249659 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Rebecca Ann Rakow-Penner · 2021 to 2026
$3.8M
NCI NIH HHS R37 CA249659NIH HHS R37CA249659
6 · The paper itself

Abstract

The diagnosis, treatment, and management of gynecologic malignancies benefit from both positron emission tomography/computed tomography (PET/CT) and MRI. PET/CT provides important information on the local extent of disease as well as diffuse metastatic involvement. MRI offers soft tissue delineation and loco-regional disease involvement. The combination of these two technologies is key in diagnosis, treatment planning, and evaluating treatment response in gynecological malignancies. This review aims to assess the performance of PET/MRI in gynecologic cancer patients and outlines the technical challenges and clinical advantages of PET/MR systems when specifically applied to gynecologic malignancies.

Indexed as

cervical cancerendometrial cancergynecological malignancyovarian cancerPET/MRIvaginal cancer

Identifiers

PMID38672560
PMCPMC11048306
OpenAlexW4394767496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.